Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
Crossref DOI link: https://doi.org/10.1007/s40259-015-0130-9
Published Online: 2015-06-30
Published Print: 2015-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hirsh, Vera
Funding for this research was provided by:
Boehringer Ingelheim
License valid from 2015-06-01